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ED3 mutants of the MAb 1A1D-2 structural epitope residues to determine the functional epitope of this
MAb. The side-chains of residues K307, K310 and I312 were determined to be functionally critical for MAb
binding, and thus constitute a hot spot of binding energy for MAb 1A1D-2 on the DENV-2 ED3. Overall,
these ﬁndings demonstrate that only a subset of the amino acid residue side-chains within the structural
epitope of MAb 1A1D-2 deﬁne a functional epitope on the DENV-2 ED3 that is essential for MAb binding and
neutralization escape.lsevier Inc.© 2010 Published by Elsevier Inc.Introduction
The dengue viruses (DENVs) consist of four genetically and anti-
genically related viruses (DENV-1, DENV-2, DENV-3, and DENV-4)
that are major human pathogens. The DENVs are ﬂaviviruses and have
a positive-sense, single-stranded RNA genome of approximately 11 kb
in length. The genome is packaged in a relatively small enveloped
virion that is 50 nm in diameter and consists of the capsid protein (C),
membrane protein (M), and major envelope glycoprotein (E) (Kuhn
et al., 2002). The surface of the mature DENV virion is covered by 90 E
protein homodimers.
Each E protein monomer is approximately 500 amino acids in
length and the N-terminal 400 amino acids form the ectodomain,
which is composed of three structural domains (ED1, ED2, and ED3).
ED1 is centrally located in the folded monomer containing a
“molecular hinge” and ED2 contains the fusion loop, both of which
are necessary for low-pH mediated fusion of the viral envelope withthe endosomal membrane and subsequent release of viral nucleo-
capsid into the cell cytoplasm (reviewed by Stiasny and Heinz,
2006). ED3 is roughly comprised of amino acids 300–400 and is
structurally deﬁned as a protease-resistant 9 kDa fragment of the E
protein (Mason et al., 1989; Roehrig et al., 1998; Winkler et al.,
1987). It has been shown for a variety of ﬂaviviruses that the
antigenic structure of ED3 depends on the conservation of a disulﬁde
bond, Cys302–Cys333 (Mason et al., 1989; Roehrig et al., 2004;
Winkler et al., 1987). This self-forming disulﬁde bond can be
reversibly denatured. For DENV-2, either reduction or ablation of
this disulﬁde bond results in the loss of DENV-2 ED3 epitopes, B2, B3,
and B4, deﬁned by MAbs 9A3D-8, 10A4D-2, and 1A1D-2, respec-
tively (Roehrig et al., 1998, 2004). Several lines of evidence suggest
that ED3 contains a receptor binding domain: (1) ED3 has an
immunoglobulin-like fold that is characteristic of many cell
receptors and displays loops that project further from the virion
surface than either ED1 or ED2; (2) ED3-speciﬁc MAbs are the most
efﬁcient at blocking virus attachment to Vero cells (Crill and Roehrig,
2001); and (3) soluble forms of ED3 can block infection of cells for
West Nile virus (WNV), DENV-2 and Langat virus (Bhardwaj et al.,
2001; Chin et al., 2007; Chu et al., 2005; Hung et al., 2004).
Table 1
Properties of MAbs 1A1D-2, MDVP-55A, and 3H5.
MAb clone Isotype DENV
rED3
speciﬁcity
KD,app with
DENV-2 rED3
(nM)
KD,app with
DENV-2 NGC
virus (nM)
[PRNT50] with
DENV-2 NGC
(nM)
1A1D-2 IgG2a 1,2,3a 0.07±0.01 0.23±0.01 2.1±0.1
MDVP-55A IgG2a 1,2,3 0.13±0.02 0.30±0.03 3.0±0.2
3H5 IgG1 2 4.3±0.7 2.8±0.1 4.6±0.8
bValues for MAbs MDVP-55A and 3H5 have been reported previously (Gromowski and
Barrett, 2007; Gromowski et al., 2008).
a Speciﬁcity of MAb 1A1D-2 has been determined previously by (Roehrig et al., 1998)
by ELISA with DENV 1-4 viruses and was conﬁrmed here by ELISA with rED3s from
DENV-1 OBS7690, DENV-2 NGC, DENV-3 H87, and DENV-4 703-4 (data not shown).
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neutralization sites (Roehrig, 2003) and several ED3 neutralizing
epitopes have been mapped for the DENVs. The epitopes of a panel of
DENV-2 type-speciﬁc and DENV subcomplex-/complex-speciﬁc
monoclonal antibodies (MAbs) have been previously identiﬁed
using random mutagenesis and yeast surface display of the DENV-2
ED3 (Sukupolvi-Petty et al., 2007). Site-directed mutagenesis of
recombinant ED3s (rED3s) have been used to map the epitope of a
DENV complex-speciﬁc MAb on the DENV-1 ED3 (Lisova et al., 2007),
the antigenic sites recognized by a panel of DENV-2 type-speciﬁc and
DENV subcomplex-/complex-speciﬁc MAbs on the DENV-2 ED3
(Gromowski and Barrett, 2007; Gromowski et al., 2008), and DENV
subcomplex-/complex-speciﬁc MAbs on the DENV-3 ED3 (Matsui
et al., 2009;Wahala et al., 2010). The epitope of a single DENV-2 type-
speciﬁc MAb was determined using mutagenesis of a DENV-2
infectious clone (Hiramatsu et al., 1996). Additionally, ED3-speciﬁc
MAb neutralization resistant viruses have been selected for using a
DENV-2 type-speciﬁc IgM MAb (Lok et al., 2001), a DENV-2 type-
speciﬁc IgG2a MAb (Lin et al., 1994), and a DENV-3 type-speciﬁc IgM
MAb (Seraﬁn and Aaskov, 2001).
MAb 1A1D-2 is a DENV ED3 sub-complex-speciﬁc IgG2a neutral-
izing MAb (Roehrig et al., 1998). The amino acids deﬁning the epitope
of this MAbwere mapped (Sukupolvi-Petty et al., 2007) to a relatively
linear stretch of residues in the DENV-2 ED3 (G304, K305, K307, and
K310); mutation of any of these residues reduced the binding of this
MAb by greater than 80% compared to thewild-type ED3. Of particular
interest was the observation that a variety of amino acid substitutions
of residue K307, including asparagine (N), glutamine (Q), isoleucine
(I), and glutamic acid (E) all reduced binding of MAb 1A1D-2 equally.
Another study used DENV-2 virus-like particle (VLP) mutants and
showed reduced reactivity of MAb 1A1D-2with K305E, K310E, E311R,
P364R, and K388D substitutions, individually (Crill et al., 2009).
Recently, the crystal structure of the Fab of the MAb 1A1D-2 in
complex with a recombinant DENV-2 ED3 was determined and a total
of 11 ED3 residues were shown to contact MAb 1A1D-2, including
K305, F306, K307, V308, V309, K310, I312, Q325, P364, K388, and
N390 (Lok et al., 2008). However, the individual contribution of these
residues to the overall binding avidity of MAb 1A1D-2 with ED3 of
DENV-2 is unknown.
In this study we assessed the functional importance of individual
crystallographic contact residue side-chains using site-directed
mutagenesis of a rED3. The functional importance of additional
residues located outside the structural epitope was also tested. The
binding avidity of MAb 1A1D-2 with each mutant rED3 was
determined. Only three ED3 contact residue side-chains identiﬁed in
the crystal structure were functionally essential for binding. Several
residues outside the structural epitope were also found to affect
binding. TwoMAb 1A1D-2 neutralization resistant variants of DENV-2
NGC were selected and sequenced. Both escape mutants had
substitutions at residue 307, one of the three amino acid side-chains
deﬁned as being functionally critical for MAb 1A1D-2 binding to ED3.
Overall, this study improves our understanding of the role of
functional epitope residues in the DENV-2 ED3 for MAb binding and
explains why mutations of these residues are selected from the virus
population, resulting in neutralization escape.
Results
Characterization of MAb 1A1D-2
The apparent dissociation constant (KD,app) of MAb 1A1D-2 to the
DENV-2 NGC rED3 protein was measured as 0.07±0.01 nM, a value
that is similar to previously characterized DENV subcomplex-/
complex-speciﬁc MAbs (Gromowski et al., 2008) (Table 1, DENV
subcomplex-/complex-speciﬁc MAb MDVP-55A is shown for com-
parison). MAb 1A1D-2 and the DENV subcomplex-/complex-speciﬁcMAb MDVP-55A bound more avidly to the DENV-2 rED3 than
previously characterized DENV-2 type-speciﬁc MAbs (MAb 3H5 is
shown in Table 1 as an example). MAb 1A1D-2 was also tested for its
avidity to virion-associated ED3 as measured by an antibody-
sandwich ELISA with puriﬁed virus. The KD,app was 0.23±0.01 nM,
again consistent with previously characterized DENV subcomplex-/
complex-speciﬁc MAbs, such as MDVP-55A (Table 1). There was
about a 3-fold, statistically signiﬁcant difference between the KD,app
obtained for virion-associated ED3 compared with the rED3, suggest-
ing that there is a subtle difference in how the 1A1D-2 epitope is
presented on the virion compared to the rED3.
The ability of MAb 1A1D-2 to neutralize DENV infectivity was
quantiﬁed using a plaque reduction neutralization test (PRNT). The
PRNT50 concentration with DENV-2 strain NGC was 2.1±0.1 nM,
similar to that of other ED3-speciﬁc MAbs such as MDVP-55A and 3H5
(Table 1). This value was approximately 10-fold higher than the KD,app
for virion-associated ED3.
Occupancy of ED3 on the virion and neutralization of infectivity
The ELISA binding data with puriﬁed virus as antigen was
translated to percent relative occupancy as described previously
(Gromowski and Barrett, 2007) (see Materials and methods) and
compared to the neutralization curve of virus infectivity as a
function of MAb concentration (Fig. 1a). The occupancy data were
best ﬁt by a standard ligand binding curve and the neutralization
data by a dose-response curve having a variable slope factor. The
curve for relative occupancy of ED3 on the virion as a function of
MAb concentration had a slope factor of −1.0±0.0 and a KD,app
value of 0.23±0.01 nM (Fig. 1a). The curve for percent neutraliza-
tion of virus infectivity as a function of MAb concentration had a
slope factor of −1.6±0.1 and a PRNT50 concentration of 2.1±
0.1 nM (Fig. 1a). Percent neutralization of virus infectivity was
plotted as a function of percent relative occupancy of ED3 on the
virion by MAb 1A1D-2 (Fig. 1b). The majority of virus infectivity was
neutralized at very high relative occupancy levels, which is
consistent with previously studied DENV subcomplex-/complex-
speciﬁc MAbs (Gromowski et al., 2008). Analogous curves for the
DENV-2 type-speciﬁc MAb 3H5 and the DENV subcomplex-/
complex-speciﬁc MAb MDVP-55A are shown in Fig. 1b for compar-
ison. For MAb 1A1D-2 the estimated average occupancies required
to achieve 0% (threshold), 10%, 50%, and 90% neutralization of
infectivity were approximately 58%, 75%, 91%, and 96% respectively.
Lok et al. (2008) reported that the Fab 1A1D-2 was capable of
binding 120 of the 180 possible ED3s per virion. This translates to
actual MAb occupancies per virion of about 70, 90, 109, and 115 to
achieve 0% (threshold), 10%, 50%, and 90% neutralization of
infectivity, respectively. The absolute absorbance values at satura-
tion with puriﬁed virus were 1.36±0.03, 1.46±0.05, and 1.42±
0.02 for MAbs 3H5, MDVP-55A, and 1A1D-2, respectively. There was
no statistical difference between these values, which indicates that
all three MAbs engage identical numbers of ED3 epitopes on the
Fig. 1. Relationship between relative occupancy and neutralization for MAb 1A1D-2.
Panel a shows the percent relative occupancy of available ED3 binding sites on the
DENV-2 virion and percent neutralization of virus infectivity as a function of
the concentration of MAb 1A1D-2. The relative occupancy curve has a slope factor
of−1.0±0.0, while the neutralization curve has a much steeper slope factor of−1.6±
0.1. Error bars represent the standard error of the mean (SEM). Panel b shows the
percent virus infectivity neutralized as a function of percent relative occupancy of
available ED3 binding sites on the virion by MAb 1A1D-2. The majority of virus
infectivity is neutralized at very high relative occupancy levels. Similar data for the
DENV-2 type-speciﬁc MAb 3H5 and DENV subcomplex-/complex-speciﬁc MAb
MDVP-55A, reported previously (Gromowski and Barrett, 2007; Gromowski et al.,
2008), are shown for comparison. MAb 3H5 neutralizes virus infectivity over a broad
range of occupancies and there is a more linear relationship between occupancy and
neutralization. In comparison, MAbs 1A1D-2 and MDVP-55A neutralize virus
considerably less efﬁciently.
Table 2
Binding avidity and changes in binding free energy of rED3 mutants with MAb 1A1D-2.
rED3 KD,app (nM) Relative KD,app
(mut/wt)
ΔΔG(mut-wt)
(kcal/mol)a
Wt 0.07±0.01 1.00 n/a
Structural epitope residuesb
K305G 0.15±0.04 2.14 0.5
K305A 0.05±0.01 0.71 −0.2
K307G N10 N143 N3
K307A N10 N143 N3
K307Tc N10 N143 N3
K307Qc N10 N143 N3
V308A 0.13±0.01 1.8 0.4
V309G 0.06±0.00 0.9 −0.1
K310Ed* N10 N143 N3
K310G N10 N143 N3
K310A N10 N143 N3
I312F* 2.5±0.3 36 2
I312A 3.1±0.4 45 2
Q325A 0.04±0.01 0.6 −0.3
P364A 0.06±0.00 0.9 −0.1
K388G 0.04±0.01 0.6 −0.3
K388A 0.04±0.00 0.6 −0.3
N390D* 0.03±0.01 0.4 −0.5
N390H* 0.03±0.01 0.4 −0.5
N390S* 0.05±0.00 0.7 −0.2
Residues outside structural epitope
K295G 0.09±0.02 1.3 0.2
S298G 0.05±0.00 0.7 −0.2
Y299I* 0.05±0.00 0.7 −0.2
S300L* 0.09±0.01 1.3 0.2
M301A 0.03±0.00 0.4 −0.5
T303G 0.05±0.00 0.7 −0.2
E311G 0.45±0.14 6.4 1.1
E311A 0.31±0.07 4.4 0.9
E327G 0.11±0.02 1.6 0.3
D329E* 0.17±0.03 2.4 0.5
D329G 0.28±0.09 4.0 0.8
G330D* 0.04±0.00 0.6 −0.3
S331A* 0.03±0.00 0.4 −0.5
S331P* 0.17±0.04 2.4 0.5
P332G 1.90±0.54 27. 2.0
P332A N10 N143 N3
K334Q* 0.05±0.01 0.7 −0.2
E338G 0.05±0.00 0.7 −0.2
K344N* 0.06±0.00 0.9 −0.1
R345K* 0.06±0.01 0.9 −0.1
R345G 0.06±0.00 0.9 −0.1
T359I* 0.05±0.01 0.7 −0.2
T359G 0.06±0.00 0.9 −0.1
E360G* 0.08±0.02 1.1 0.1
K361G 0.29±0.03 4.1 0.8
D362G 0.11±0.02 1.6 0.3
S363R* 0.07±0.01 1.0 0.0
E383A 0.05±0.00 0.7 −0.2
P384G 1.34±0.85 19.1 1.8
P384A 0.50±0.27 7.1 1.2
G385E* 0.04±0.01 0.6 −0.3
L387A 0.27±0.08 3.9 0.8
L389A 0.45±0.29 6.4 1.1
W391A 7.02±2.49 100 2.7
a Calculated as+RTln(KD,app mutant/KD,app wild-type), where R is the gas constant
and T is the absolute temperature.
b Structural epitope residue F306 was not tested because it does not have a surface
accessible side-chain.
c Mutations identiﬁed in MAb 1A1D-2 neutralization resistant variants that were
isolated in this study.
d Naturally occurring substitutions are denoted by an asterisk (*).
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2008 study).
Binding avidity of rED3 mutants with MAb 1A1D-2
A panel of 55 rED3 mutants (Table 2) containing single
substitutions of surface accessible amino acid residues, many of
which have been described previously (Gromowski and Barrett,
2007; Gromowski et al., 2008), were interrogated for binding with
MAb 1A1D-2. Mutations included both naturally occurring substitu-
tions and glycine and/or alanine substitutions of conserved residues
(naturally occurring substitutions are denoted with an asterisk [*] in
Table 2). The KD,app for MAb 1A1D-2 was determined by titration in
an indirect ELISA with all 55 rED3 mutant proteins and compared to
the wild-type (Wt) rED3. The analysis of functionally important
residues was carried out as previously described (Gromowski andBarrett, 2007; Gromowski et al., 2008), where functionally critical
residues were deﬁned as those having a ≥10-fold reduction in
avidity (≥1.3 kcal/mol energy contribution), residues with a weak
functional importance were those having a 4- to 10-fold reduction in
avidity (0.8 to 1.3 kcal/mol energy contributions), and any changes
240 G.D. Gromowski et al. / Virology 407 (2010) 237–246in avidity of less than 4-fold (b0.8 kcal/mol energy contribution)
were not considered signiﬁcant.
Lok et al. (2008) found that a total of 11 DENV-2 ED3 residues
contacted the Fab of MAb 1A1D-2, including K305, F306, K307, V308,
V309, K310, I312, Q325, P364, K388, and N390. Of these structural
epitope residues, we found that mutations K307G/A/T/Q and K310E/
G/A resulted in reductions in avidity of greater than 143-fold,
corresponding to apparent binding energy contributions of more
than 3 kcal/mol (Table 2 and Fig. 2a). Mutant I312F/A resulted in 36-
and 45-fold reductions in avidity respectively, which corresponds to
about 2 kcal/mol apparent binding energy contributions. (Table 2 and
Fig. 2a). The other seven structural epitope residues tested had 2-fold
or lower changes in avidity and individually contributed little to the
binding energy (−0.5 to 0.5 kcal/mol) (Table 2 and Fig. 2a). Structural
epitope residue F306 was not tested as it has a side-chain that is
buried within ED3.
A total of 27 residues outside of the structural epitope of MAb
1A1D-2 have been previously mutated and recovered ED3s used to
map functionally important residues for other MAbs (Gromowski and
Barrett, 2007; Gromowski et al., 2008). This particular set of mutants
was used in the current study with MAb 1A1D-2 to establish a
comparison to those epitopes mapped previously and put these
previous results in context with the structurally deﬁned epitope of
MAb 1A1D-2. A few residues (P332 and W391) outside the structural
epitope critically affected 1A1D-2 binding (Fig. 2b, in red). A subset of
the mutants outside the structural epitope had weak effects on
binding avidity when mutated and were also considered functionally
important for MAb 1A1D-2 binding. These residues included E311,
D329, K361, P384, and L389 (Fig. 2b, in pink). The functionally
important residues located outside the structural epitope for MAb
1A1D-2, with the exception of P332, cluster on ED3 in a location that is
consistent with that of functionally important residues and predicted
epitopes of other DENV subcomplex-/complex-speciﬁc MAbs
(Gromowski et al., 2008; Lisova et al., 2007; Sukupolvi-Petty et al.,Fig. 2. (a) Structural epitope of MAb 1A1D-2 on the DENV-2 ED3 described by Lok et al. (
binding free energy (ΔΔG [kcal/mol]) as determined by site-directed mutagenesis of a DEN
for MAb 1A1D-2 on ED3, while the other contact residues individually contribute much le
MAb 1A1D-2 and examples of two previously characterized DENV ED3-speciﬁc neutralizi
red and functionally weak residues (4- to 10-fold reductions in avidity) are shown in pin
speciﬁc MAb 3H5 are shown for comparison. In particular, residue K307 was critical for
diagrams are based on the crystal structure of the DENV-2 E protein (PDB-ID: 10KE). Th
previously (Gromowski and Barrett, 2007; Gromowski et al., 2008).2007). The functionally important structural epitope residues are also
included in Fig. 2b (K307, K310 and I312, in red) for comparison with
previously identiﬁed functionally important residues for DENV
subcomplex-/complex-speciﬁc MAb MDVP-55A and DENV-2 type-
speciﬁc MAb 3H5.
It is important to point out that each MAb has a unique set of
functionally critical/weak residues for binding, suggesting that these
interactions are speciﬁc to theMAb being tested and are not a result of
global effects on the protein. Circular dichroism spectroscopy was
undertaken for the critical ED3mutants K305A, K310A and P384A and
results showed that even though the residues were critical for binding
of MAbs they all folded correctly, having secondary structure that is
typical of primarily beta-sheets and was nearly identical to the Wt
ED3 (Fig. 3). In addition, these mutants do not have free -sulfhydryl
groups indicating the disulﬁde bond in ED3 is intact and the proteins
are folded properly (Table 3).
Amino acid substitutions in ED3 of MAb 1A1D-2 neutralization
resistant variants
Two MAb 1A1D-2 neutralization resistant variants of DENV-2
strain NGC were isolated and the ED3 nucleotide sequence for each
variant was compared to a DENV-2 NGC passage control virus. The
ﬁrst variant had only one change from A to C at nucleotide 1856 of the
genome (nucleotide 920 of the E gene). The nucleotide change
resulted in a substitution of lysine (K) for threonine (T) at amino acid
residue 307 of ED3. The second variant had three changes; A to C at
nucleotide 1855 of the genome (nucleotide 919 of the E gene), T to C
at nucleotide 2022 of the genome (nucleotide 1086 of the E gene), and
C to T at nucleotide 2034 of the genome (nucleotide 1098 of the E
gene). The ﬁrst change at nucleotide 1855 resulted in a substitution of
lysine (K) for glutamine (Q) at amino acid residue 307 of ED3 and the
other two changes were silent. When K307T and K307Q substitutions
were introduced into the rED3, binding of MAb 1A1D-2 was2008). Each residue has been color-coded to denote their apparent contributions to
V-2 rED3 in this study. Residues K307, K310, and I312 are hot spots of binding energy
ss to the binding free energy. (b) A comparison of functionally important residues for
ng MAbs. Functionally critical residues (≥10-fold reduction in avidity) are shown in
k. The DENV subcomplex-/complex-speciﬁc MAb MDVP-55A and the DENV-2 type-
the functional epitope of MAb 1A1D-2 but not for the other ED3-speciﬁc MAbs. The
e functionally important residues for MAbs MDVP-55A and 3H5 have been reported
Fig. 3. Circular dichroism spectra of DENV-2 -rED3. (black), rED3-P384A; (red), rED3-
K305A; and (blue), rED3-K310A in TN200 buffer (20 mM Tris, 200 mMNaCl, 1 mM EDTA
and 5% glycerol(v/v)) at 20 °C and pH8.0. Protein concentrations were: K305A, 0.32 mg/
ml; K310A, 0.03 mg/ml; and P384A, 0.08 mg/ml.
Table 4
Relative dissociation constant (KD,app) of K307 mutant rED3s with MAb 1A1D-2 and a
panel of DENV ED3-speciﬁc MAbs.
MAb rED3
Wt K307G K307A K307T K307Q
1A1D-2 1.0 N143 N143 N143 N143
GTX29202 1.0 5.1 3.5 1.2 1.1
GTX77557 1.0 7.0 3.7 1.5 1.2
MDVP-55A 1.0 14.0 4.4 2.5 1.5
MA1-27093 1.0 3.0 2.8 1.9 0.8
20-783-74014 1.0 5.4 2.8 1.9 0.6
3H5 1.0 1.1 2.5 0.4 1.0
M8051122 1.0 1.2 1.4 0.9 1.1
9F16 1.0 4.4 2.1 1.0 1.2
2Q1899 1.0 3.3 2.8 0.4 0.5
IP-05-143 1.0 1.5 1.4 1.4 1.5
GTX77558 1.0 4.0 2.1 2.1 2.6
5C36 1.0 1.8 1.7 1.3 1.3
aRelative KD,app with K307G/A mutants has been reported previously for all MAbs
except 1A1D-2 (Gromowski and Barrett, 2007; Gromowski et al., 2008).
Table 5
Neutralization indices of the DENV-2 NGC passage control and K307 variants with MAb
1A1D-2 and a panel of DENV ED3-speciﬁc MAbs.
MAb Neutralization Index (Log10 PFU)a
Passage control K307T K307Q
1A1D-2 2.1±0.2 0.0±0.2 0.0±0.2
GTX29202 1.8±0.2 1.8±0.2 1.2±0.0
MDVP-55A 2.0±0.2 2.6±0.2 1.9±0.0
GTX77557 1.9±0.2 2.0±0.2 1.6±0.1
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(N3 kcal/mol) (Table 2). These mutations had little effect on 12 other
ED3-speciﬁc MAbs, resulting in less than 4-fold changes in avidity
(Table 4). This conﬁrmed that the mutations at residue K307 of ED3 of
the MAb 1A1D-2 neutralization resistant variants were sufﬁcient for
neutralization escape and speciﬁc for MAb 1A1D-2.
Neutralization of MAb 1A1D-2 neutralization resistant variants
MAb 1A1D-2 and a large panel of previously characterized DENV
ED3 subcomplex-/complex-speciﬁc and DENV-2 ED3 type-speciﬁc
neutralizing MAbs (Gromowski and Barrett, 2007; Gromowski et al.,
2008) were examined in a PRNT assay with both 1A1D-2 neutraliza-
tion resistant variants, as well as the DENV-2 NGC passage control
virus. The neutralization index was determined for each MAb/virus
combination (Table 5). MAb 1A1D-2 neutralized 2.1±0.2 log10 PFU
with the DENV-2 NGC passage control virus and 0.0±0.2 log10 PFU for
both the K307T and K307Q variants. The other twelve MAbs
neutralized all three viruses strongly.
Phenotypic characteristics of MAb 1A1D-2 resistant variants
The plaque morphology of each of the viruses was examined in
Vero cells on day 8 post infection. The DENV-2 NGC passage control
virus had a large plaque morphology (N1.5 mm; Fig. 4a), as did the
K307T variant (Fig. 4b). The K307Q variant, however, had a small
plaque phenotype (b1 mm; Fig. 4c) and the plaques were visible
2 days later than the DENV-2 NGC passage control virus or the K307T
variant.
The MAb 1A1D-2 neutralization resistant variants were tested in
multi-step multiplication curve analysis for their ability to replicate in
Vero cells to determine if the substitution at residue 307 of ED3
affected growth kinetics (Fig. 4d). The K307T variant multiplied
similarly to the DENV-2 NGC passage control virus but had slightly
lower virus yields at days 1 to 4 post infection. Statistically signiﬁcantTable 3
Summary of SH determination by Ellman's reagent.
Protein Molar ratio of SH/ED3
WT 0.3±0.1
K305A 0.2±0.1
K310A 0.3±0.2
P384A 0.1±0.2differences were seen at days 2 and 3 for the K307T variant, with
approximately 0.6 and 0.5 log10 PFU lower virus titers compared to
the DENV-2 NGC passage control virus, respectively. The K307Q
variant had a signiﬁcantly lower log10 PFU virus titer at day 1 post
infection, producing approximately 1.5 log10 PFU less virus than the
DENV-2 NGC passage control virus. This variant caught up to the
passage control virus at day 2 and multiplied similarly, with only a
small but statistically signiﬁcant decrease in titer compared to the
DENV-2 NGC passage control virus at day 4 of 0.3 log10 PFU. The
sequence of ED3 for all three viruses was determined at the ﬁnal time-
point and there was no reversion to lysine (K) identiﬁed at residue
307 for either neutralization resistant variant and no additional amino
acid substitutions were identiﬁed.
The multi-step multiplication kinetics of the MAb resistant
variants were also tested in mosquito C6/36 cells (Fig. 4e). The
K307T variant multiplied with similar kinetics to the DENV-2 NGC
passage control virus, but had statistically lower titers at days 3 and 4
of 0.5 and 0.8 log10 PFU lower respectively. This variant, however, had
a statistically higher peak titer that was approximately 0.8 log10 PFU
higher on days 6 and 7 post infection. The K307Q variant had
statistically lower titers at days 2, 3, and 4 of about 0.5, 0.7, and 1.5
log10 PFU lower, respectively. This variant had similar multiplication
kinetics to the DENV-2 NGC passage control virus on days 6 to 8. As
was seen with Vero cells, no reversion to lysine (K) occurred at
residue 307 and there were no additional amino acid substitutions
identiﬁed at the ﬁnal time-point for either neutralization resistant
variant.MA1-27093 1.9±0.1 2.0±0.2 2.0±0.1
20-783-74014 1.7±0.1 1.6±0.2 1.5±0.1
3H5 2.5±0.2 3.2±0.2 2.5±0.1
M8051122 2.4±0.2 2.5±0.2 2.0±0.0
9F16 1.3±0.1 2.1±0.0 1.2±0.1
2Q1899 1.8±0.1 2.6±0.1 2.0±0.1
IP-05-143 2.9±0.2 2.8±0.2 2.9±0.0
GTX77558 2.6±0.2 2.5±0.2 2.3±0.1
5C36 2.1±0.2 2.4±0.2 2.4±0.1
a Log10 reduction in virus titer compared to no MAb control.
Fig. 4. Plaque morphologies and multiplication kinetics of the DENV-2 NGC passage control virus and MAb 1A1D-2 neutralization resistant variants. The passage control virus is
shown in panel a and the K307T and K307Q variants are shown in panels b and c, respectively. The DENV-2 NGC passage control virus had a large plaque morphology (deﬁned
as N1.5 mm on day 8 post infection) as did the K307T variant, whereas the K307Q variant had a small plaque morphology (deﬁned as b1 mm on day 8 post infection).
Multiplication kinetics were tested in both Vero (panel d) and C6/36 (panel e) cells at a MOI of 0.001. Error bars represent the standard error of the mean (SEM).
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Based on X-ray crystallographic analysis, Lok et al. (2008) reported
that 11 DENV-2 ED3 residues contacted the Fab of MAb 1A1D-2, with
a total of 12 side-chain contacts and 8 main-chain contacts. There
were four residues with only main-chain, and no side-chain contacts
(F306, V308, K388 and N390). Therefore, the contacts made by these
four residues could not be investigated by mutagenesis of side-chains
alone, as was undertaken in our study. Of the remaining seven
residues that had side-chain contacts with MAb 1A1D-2, only those
that had two or more side-chain contacts (K307, K310 and I312)
signiﬁcantly affected MAb binding when mutated, and these were
identiﬁed as being hot spot residues in our study. The most critical
residues for binding (K307 and K310) had at least one electrostatic
side-chain contact withMAb 1A1D-2. Since residues F306, V308, K388
and N390 have only 1 main-chain contact each, which is not
electrostatic, it is unlikely that these residues are hot spots of binding
energy, even though they undoubtedly contribute to the overall
binding energy with MAb 1A1D-2. Residue V309, which has 1 side-
chain and 1main-chain contact, may have been identiﬁed as a hotspot
residue had we been able to disrupt the main-chain contact as well.
Collectively, the main-chain contacts may be important for cross-
reactivity of this MAb with other DENVs, but in the context of this
study, the side-chains are the more pertinent aspect of the binding
interaction because they vary among DENV strains.
Our results are in agreement with several previous reports that
suggest only a small number of contact residues are crucial for the
binding of antibody to antigen (Bedouelle et al., 2006; Dougan et al.,
1998; Jin et al., 1992; Kelley and O'Connell, 1993; Li et al., 2003; Lin
and Wu, 2003; Novotny et al., 1989; Nuss et al., 1993; Saphire et al.,
2001). Residues K310 and I312 are not conserved among all DENV-2strains as mutations K310E and I312F have been previously identiﬁed
in separate human isolates from Malaysia (Samuel et al., 1989a,b,c).
Of particular interest is residue K310, which is a common functionally
critical residue for many DENV ED3 subcomplex-/complex-speciﬁc
neutralizing MAbs characterized thus far (Gromowski et al., 2008;
Lisova et al., 2007; Sukupolvi-Petty et al., 2007), including this study.
Work by Crill et al. (2009) indicated that residue K310 is probably
important for the binding of some human subcomplex-/complex-
speciﬁc neutralizing antibodies to ED3 of DENV-2. Therefore, naturally
occurringmutations at residue K310may be as a result of selection for
variants capable of escaping neutralization by DENV ED3 subcom-
plex-/complex-speciﬁc antibodies. However, the importance of these
dengue cross-reactive ED3-speciﬁc antibodies for protection in
humans following a natural infection is unclear (Crill et al., 2009;
Wahala et al., 2009).
A total of seven residues located outside the structural epitope of
MAb 1A1D-2 were shown to be functionally important for binding.
Two of these residues (P332 and W391) are highly conserved among
the ﬂaviviruses and were considered critical for MAb 1A1D-2 binding
to ED3. Residue W391 is adjacent to I312, a hot spot residue, and
mutation could disrupt an important interaction. Residue P332,
however, is spatially distant from the structurally deﬁned epitope.
Substitutions at residue P332 could have allosteric effects on the
epitope of MAb 1A1D-2. Mutations at residue P332 do not have this
effect on all ED3-speciﬁc MAbs (Gromowski and Barrett, 2007;
Gromowski et al., 2008); therefore the reductions in binding avidity
are not likely due to global effects on the protein. Mutations of the
other ﬁve residues (E311, D329, K361, P384, and L389) only resulted
in weak changes in avidity (4- to 10-fold reductions) and are all in
relatively close proximity to residues identiﬁed in the structural
epitope of MAb 1A1D-2. Thus, the weak changes in avidity observed
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of ED3 structure and/or individual residues within the structural
epitope.
The location of the structural epitope of MAb 1A1D-2 (Lok et al.,
2008) is similar to that of predicted epitopes for other DENV
subcomplex-/complex-speciﬁc MAbs (Gromowski et al., 2008; Suku-
polvi-Petty et al., 2007), based on mapping functionally important
residues for binding. Therefore, it was not surprising thatMAb 1A1D-2
neutralized virus infectivity at only very high relative occupancy
levels, as this has been previously demonstrated for MAbs that
recognize this particular antigenic site on the DENV-2 ED3
(Gromowski et al., 2008). In contrast, MAbs that recognize an
adjacent DENV-2 or WNV type-speciﬁc antigenic site (such as
DENV-2 MAb 3H5 or WNV MAb E16) neutralize virus infectivity
much more efﬁciently (Gromowski and Barrett, 2007; Pierson et al.,
2007). These data demonstrate the value of predicting MAb epitopes
by identifying functionally important residues for binding, and
conﬁrm previous observations (Gromowski et al., 2008) of a
correlation between the DENV-2 ED3 epitope recognized by a MAb
and neutralization efﬁciency.
The functional epitope of MAb 1A1D-2 on the DENV-2 ED3 is only
partially conserved among the four DENVs within the linear sequence
of ED3 (see Table 6). Of the three functional epitope residues
identiﬁed, only K310 is conserved among the four DENVs. Residues
K307 and I312 vary between the four DENVs, with K307 being
conserved in DENV-1 only, and I312 not being conserved among any
of the other DENVs. The homologous residue for I312 of DENV-2 is a
valine (V) for DENV-1 and -3, which is a very conservative difference
as their side-chains are comparable in size and are hydrophobic. For
DENV-4 the homologous residue for I312 is a methionine (M), which
is a hydrophobic residue but has a larger side-chain compared to
either isoleucine (I) or valine (V). The differences for residue K307 are
much less conservative with the homologous residues being valine
(V) for DENV-3 and serine (S) for DENV-4. Sukupolvi-Petty et al.
(2007) demonstrated signiﬁcant losses in binding of MAb 1A1D-2 to
the DENV-2 ED3 with substitutions of asparagine (N), glutamine (Q),
isoleucine (I), and glutamic acid (E) at residue 307. Furthermore, we
demonstrate that substitutions of glycine (G), alanine (A), threonine
(T), and glutamine (Q) at residue 307 resulted in a signiﬁcant loss of
MAb 1A1D-2 avidity (N143-fold reduction in avidity; N3 kcal/mol
apparent binding energy contribution) for the DENV-2 ED3. Thus, the
lack of conservation of residue K307 among the four DENVs may, in
part, explain why MAb 1A1D-2 cannot bind or neutralize all four
DENVs equally (Lok et al., 2008; Roehrig et al., 1998). However,
identifying similarities in the linear sequence of ED3 between the four
DENVs has poor predictability for the binding avidity and neutrali-
zation efﬁcacy of DENV subcomplex-/complex-speciﬁc MAbs
(Gromowski et al., 2008). This suggests that other factors may be
involved such as the use of an alternative network of interactions
among critical residues for binding, which has been observed for
DENV-2 and DENV-3 (Matsui et al., 2009), and/or main-chain
contacts, as observed by Lok et al. (2008).
Isolation of DENV-2 neutralization resistant variants with sub-
stitutions at residue 307 of ED3 indicates that MAb 1A1D-2
functional epitope mutations can be exploited in order to escape
neutralization. For the DENVs, ED3-speciﬁc MAb neutralization
resistant variants have had single substitutions at residues K307Table 6
Conservation of critical functional epitope residues of MAb 1A1D-2 in the linear
sequence of ED3 among the four DENVs.
Position DENV-2 DENV-1 DENV-3 DENV-4
307 K K V S
310 K K K K
312 I V V M(Lin et al., 1994) and E311 (Lok et al., 2001) for DENV-2, as well as
K386 for DENV-3 (Seraﬁn and Aaskov, 2001), and these residues
may also represent binding energy hot spots for their respective
MAbs. In our study, the DENV-2 K307T and K307Q variants were not
resistant to neutralization by the other 12 DENV ED3 type- or
subcomplex-/complex-speciﬁc MAbs. This was not surprising as
residue K307 was not identiﬁed as being functionally critical for any
of these MAbs (Gromowski and Barrett, 2007; Gromowski et al.,
2008). Multiplication kinetics of these DENV-2 neutralization
resistant variants in monkey kidney Vero cells or mosquito C6/36
cells was not drastically altered, which suggests that residue K307 is
not functionally critical for multiplication in either cell type. In
particular, the low MOI (0.001) that was used for these experiments
suggests that there is no signiﬁcant blockage at any stage in the
multiplication cycle (including binding/entry). The K307Q variant,
however, had a markedly smaller plaque size in Vero cells compared
to either the DENV-2 NGC passage control virus or the K307T variant.
This may be indicative of an attenuated phenotype and could be
linked to the initial lag in multiplication kinetics observed in Vero
cells at 1 dpi with the K307Q variant, but this requires further
investigation.
In this study we characterized the functional epitope of a DENV
subcomplex-speciﬁc MAb on ED3. Our results agree with data from
other MAb/antigen combinations and indicate that only a small
subset of the residues in the MAb 1A1D-2 structural epitope are
functionally critical for binding. Additionally, in the case of DENV-2,
we demonstrated that mutations of antibody binding energy hot spot
residues on ED3 can be selected for as a means of escaping antibody
neutralization, providing that the mutated residue is not functionally
critical for viral replication or spread. Overall, these data expand our
understanding of the interactions between neutralizing antibodies
and the DENV-2 ED3, and may be helpful for the rational design of
DEN vaccines or antiviral drugs that target conserved, functionally
critical neutralizing epitopes on ED3.Materials and methods
Cells and viruses
Monkey kidney Vero cells were maintained at 37 °C in a 5% CO2
incubator in Dulbecco's modiﬁed essential media (DMEM) containing
8% fetal bovine serum (FBS). Mosquito C6/36 cells weremaintained at
28 °C in DMEM containing 10% FBS and supplemented with tryptose
phosphate buffer. The DENV strain used in this study was DENV-2
NewGuinea C (NGC). Primary virus stocks were passaged twice in C6/
36 mosquito cells to obtain sufﬁcient titers.Puriﬁcation of virus
C6/36 mosquito cells were grown in an 850-cm2 roller bottle and
infected with DENV-2 NGC at an MOI of approximately 0.1. The
infected cell supernatant was harvested on day 7 post infection. Cell
debris was removed by centrifugation at 5000 rpm for 30 min at
4 °C. The supernatant was layered on top of a 30% sucrose solution
containing 10 mM Tris, 100 mM NaCl, and 1 mM EDTA. Virus was
pelleted by ultracentrifugation in a swinging bucket rotor at
26,000 rpm for 4 h at 4 °C to remove low molecular weight
contaminants such as soluble proteins. The supernatant was
decanted and the tubes were brieﬂy left upside down on chroma-
tography paper in order to remove excess liquid from the side of
the tubes. The virus pellet was resuspended in PBS. The infectious
titer was determined by a standard plaque assay in Vero cells.
The purity of the virus preparations was veriﬁed by SDS-PAGE (data
not shown).
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MAb 1A1D-2 (Roehrig et al., 1998) was used as mouse immune
ascitic ﬂuid or protein A afﬁnity puriﬁed antibody. Additionally,
twelve commercially available, afﬁnity puriﬁed, murine MAbs were
used in this study: GTX29202 (GeneTex), GTX77557 (GeneTex), and
MDVP-55A (Immunology Consultants Laboratory, Inc.), MA1-27093
(Afﬁnity BioReagents), 20-783-74014 (GenWay), 3H5 (Chemicon)
(Gentry et al., 1982), M8051122 (Fitzgerald Industries), 9F16 (US
Biological), 2Q1899 (US Biological), 5C36 (US Biological), IP-05-143
(RayBiotech, Inc.), and GTX77558 (GeneTex).
Expression and puriﬁcation of recombinant DENV-2 ED3
The region corresponding to ED3 (amino acids 295–395 of the E
protein) of DENV-2 strain New Guinea C (NGC) genomic RNA was
reverse-transcription PCR ampliﬁed for cloning and expression in
Escherichia coli DH5α as maltose binding protein (MBP) fusions using
the pMal-c2x system (New England Biolabs, Berverly MA), as
previously described (Gromowski and Barrett, 2007). Recombinant
ED3s for DENV-1 strain OBS7690, DENV-3 strain H87, and DENV-4
strain 703–4 were also cloned and expressed this way. Protein
concentrations were determined by spectrophotometric analysis. The
molar extinction coefﬁcient (ε) for the rED3 was estimated to be
76,570 M−1 cm−1. This value was derived from the equation ε=
(nW×5500)+(nY×1490)+(nC×25); where W is tryptophan, Y is
tyrosine, C is cysteine, n is the total number of each residue, and the
stated values are their molar absorptivities at 280 nm. The molecular
weight of the rED3 was estimated as 56.5 kDa. At a 280-nm
wavelength, an absorbance reading of 1.355 was approximately
equal to a 1 mg/ml protein concentration.
Mutagenesis of recombinant DENV-2 ED3
Site-directed mutagenesis of the DENV-2 NGC ED3 gene fragment
in the pMal-c2x vector was done using the Quickchange kit
(Stratagene, La Jolla, CA) according to the manufacturer's instructions.
Circular dichroism spectroscopy
CD measurements were performed on an AVIV model 60 DS
spectropolarimeter. Far-UV CD spectra of the rED3s in the native state
(in TN200 buffer) at room temperature were measured over the
ranges of 260–200 nmusing a 1.0 mm-path length cell. Each spectrum
was recorded in 0.5 wavelength increments. For each rED3, 3
repetitive scans were obtained, averaged and baseline-corrected.
Test for free–SH groups
Free sulfhydryl groups were determined by the Ellman reagent
(5,5′-dithiobis(2-nitrobenzoic acid, Sigma-Aldrich) (Ellman GL
(1959). Brieﬂy, 6 to 20 μM of ED3 in TN200 buffer were mixed
with 100 μM of Ellman's reagent at room temperature for at least
5 min. Further incubation beyond 5 min did not lead to any changes
in ﬁnal results. Thus, it was concluded that the reaction was com-
plete in less than 5 min. The absorbance at 412 nmwasmonitored by
a Hitachi U-3010 spectrophotometer. The molar concentration of
free sulfhydryl group was determined by an extinction coefﬁcient of
13600 M−1 cm−1.
Avidity measurements by indirect ELISA with rED3
The wells of a 96-well microtiter plate (Corning Inc., Corning, N.
Y.) were coated with 200 ng of rED3 diluted in borate saline pH 9.0
at 37 °C for 2 h. This amount of rED3 was determined to saturate the
wells by undertaking a checkerboard serial dilution of anti-MBPantisera (NEB) and rED3, which yielded peak absorbance values that
were below the maximum range of the plate reader (data not
shown). Wells were washed twice with distilled and deionized
water (ddH20) and blocked for 30 min at room temperature (25 °C)
with blocking buffer [phosphate-buffered saline (PBS), 0.1% (v/v)
Tween-20, 0.25% (w/v) bovine serum albumin (BSA)] and subse-
quently washed twice with ddH20. PuriﬁedMAb 1A1D-2 was diluted
to 10 nM and added to duplicate wells followed by 11 two-fold serial
dilutions in blocking buffer. This range of concentrations was
determined to cover the full range of binding, from undetectable
binding to saturation, to the DENV-2 NGC rED3. MAbs MDVP-55A
and 3H5 were tested in parallel with the wild-type rED3 in order
to make comparisons with the results from previous studies
(Gromowski et al., 2008). Binding occurred overnight at room
temperature (25 °C) for 15–18 h. Subsequently, the microtiter plates
were washed twice with ddH20 and twice with PBS-T (PBS contain-
ing 0.1% Tween-20) followed by addition of a 1/1000 dilution of HRP
conjugated goat anti-mouse-immunoglobulins (Sigma) and incu-
bated for 1 h at room temperature. Following this incubation,
microtiter plates were washed twice with ddH20 and twice with
PBS-T. Antibody binding was visualized by addition of 3, 3', 5, 5'-
tetramethylbenzidene substrate (Sigma). After 30 min of incubation
at room temperature the absorbance was read at 655 nm on a model
3550-UV plate reader (Bio-Rad, Hercules, CA). Binding curves and
the apparent dissociation constant (KD,app) values were determined
by doing a non-linear regression analysis using Sigmaplot (Version
9.01, Systat Software, Inc., CA). The results are an average of two
experiments. A similar procedure was used for measuring the ability
of MAb 1A1D-2 to bind to DENV-1, -3, and -4 rED3s.
Avidity measurements and estimates of occupancy by
antibody-sandwich ELISA with puriﬁed virus
The wells of a 96-well microtiter plate (Corning Inc., Corning, N.
Y.) were coated with 50 μl of a 1/5 dilution of rabbit anti-DENV-ED3
polyclonal sera (“capture antibody”) for 2 h at 37 °C. The plates were
washed twice with PBS-T and twice with ddH20. Puriﬁed DENV-2
NGC (~5×107 PFU/mL) was diluted 1/50 in blocking buffer and
50 μl was added to each well and incubated at 37 °C for 2 h. The
remainder of the assay was undertaken as described above with the
rED3, except the primary MAb was only incubated for 1 h at room
temperature in accordance with the length of incubation used for
the virus neutralization assay. MAbs MDVP-55A and 3H5 were
tested in parallel in order to make comparisons with the results from
previous studies (Gromowski et al., 2008). Binding curves and KD,app
values were determined by non-linear regression analysis using
Sigmaplot (Version 9.01, Systat Software, Inc., CA). The results are an
average of two experiments. Generation of colored substrate, and
thus the absorbance reading in the indirect ELISA, is proportional to
the amount of antibody bound to antigen in the well. At saturation
(i.e. maximum absorbance) it is predicted that all possible ED3
binding sites on the virion are occupied by MAb. Therefore,
absorbance readings below saturation can be calculated as fractional
occupancies of the total available ED3s by MAb.
Plaque reduction neutralization test 50% (PRNT50)
Puriﬁed MAb 1A1D-2 was diluted to 80 nM and then serially
diluted 2-fold in MEM containing 2% FBS (40 nM once diluted with
virus). MAbs MDVP-55A and 3H5 were similarly tested for compar-
ison with the results from previous studies (Gromowski et al., 2008).
Virus was diluted to approximately 1 PFU/μl in MEM containing 2%
FBS. 400ul of virus (~400 PFU) was mixed with an equal volume of
MAb dilution or 400ul of MEM containing 2% FBS (control) and was
incubated at room temperature (25 °C) for 1 h. Following this
incubation, 200ul of each virus/MAb mixture, or controls, was
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monkey kidney Vero cells. Infection was allowed to take place for 1 h
at room temperature at which point the cells were washed twice with
PBS, overlaid withMEM containing 2% FBS and 1% Agar, and incubated
at 37 °C. Plaques were visualized on days 6–8 by staining with neutral
red. PRNT data were converted to percent neutralization relative to
controls in the absence of MAb and PRNT50 concentrations were
calculated by doing a non-linear regression analysis using Sigmaplot
(Version 9.01, Systat Software, Inc., CA). The data are ﬁtted by a
standard four parameter logistic curve (i.e. dose-response curve) by
the equation: y=min+(max – min) / (1+(x / EC50) slope factor). The
results are an average of three experiments.
Selection of MAb 1A1D-2 neutralization resistant variants
Approximately 107 PFU of DENV-2 NGC was mixed with MAb
1A1D-2 ascitic ﬂuid at a 1/500 dilution and incubated for 1 h at room
temperature (~25 °C). Following incubation, themixturewas added to
Vero cell monolayers and plaque assays were carried out as described
for the PRNT below. Plaques were picked and passaged twice in C6/36
cells in the presence of MAb 1A1D-2 ascitic ﬂuid (diluted 1/500 in
maintenance media). A DENV-2 NGC control was also passaged twice
in C6/36 cells. The viral RNA from cell-infected supernatant was
reverse transcription PCR ampliﬁed and sequenced. The deduced
amino acid sequence of ED3 for the variants was compared to the
passage control in order to identify amino acid substitutions involved
with escape from neutralization by MAb 1A1D-2.
PRNT with MAb 1A1D-2 neutralization resistant variants
Puriﬁed MAb 1A1D-2 and a panel of 12 previously characterized
ED3-speciﬁc MAbs (Gromowski and Barrett, 2007; Gromowski et al.,
2008) were diluted to a 320 nM concentration in PBS. These
concentrations are at least 10-fold higher than the PRNT50 concentra-
tions for these MAbs with DENV-2 NGC following dilution with an
equal volume of virus. The DENV-2 NGC passage control virus and the
two MAb resistant variants were serially diluted 10-fold in MEM
containing 2% FBS and mixed with an equal volume of MAb or PBS
only control and incubated for 1 h at room temperature (~25 °C). The
rest of the assay was carried out as described above for PRNT50. The
neutralization index was calculated as the log10 reduction in virus
titer in the presence of MAb compared with no-MAb control.
Multiplication kinetics of MAb neutralization resistant variants
Vero or C6/36 cell monolayers were infected with viruses at a
multiplicity of infection (MOI) of 0.001 PFU/cell for 1 h at room
temperature. Monolayers were rinsed three times with PBS followed
by addition of the appropriate maintenance media. Samples of the
media were taken at time 0 and then at 24-h intervals. Virus titers
were determined by plaque assay in Vero cells in triplicate per time-
point. Results are an average of two independent experiments run in
duplicate. At the ﬁnal time-point for each virus, the viral RNA was
reverse transcription PCR ampliﬁed and sequenced and the deduced
amino acid sequence of ED3 was determined to conﬁrm the presence
of the K307T/Q mutations and the absence of additional mutations.
Statistical analysis
Values are presented as themean± the standard error of themean
(SEM), where appropriate, and were analyzed using SigmaStat
(Version 3.1, Systat Software, Inc., CA). Statistical analyses were
done using one-way analysis of variance (ANOVA) followed by a
Bonferroni post hoc test with Pb0.05 required for statistical
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